EUVIMEDEUVIMED entdecken
Klinische StudieRandomisierte kontrollierte StudieOpen Access · CC BY 4.0

Safety and immunogenicity following co-administration of Yellow fever vaccine with Tick-borne encephalitis or Japanese encephalitis vaccines: Results from an open label, non-randomized clinical trial

John Tyler Sandberg, Marie Löfling, Renata Varnaitė, Johanna Emgård, Nabil Al-Tawil, Lars Lindquist, Sara Gredmark-Russ, Jonas Klingström, Karin Loré, Kim Blom, Hans-Gustaf Ljunggren iD

PLOS Neglected Tropical Diseases · 2023

DOI: 10.1371/journal.pntd.0010616 ↗

Kurz gefasst

Klinische Studie in der Zeitschrift PLOS Neglected Tropical Diseases, 2023. Verfasst von John Tyler Sandberg und 10 weiteren Autor:innen. Beteiligte Einrichtung: Center for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden. Hauptthemen laut MEDLINE: Yellow Fever Vaccine, Japanese Encephalitis Vaccines, Encephalitis, Tick-Borne, Flavivirus Infections. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Vetenskapsrådet, Stiftelsen för Strategisk Forskning, Region Stockholm.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Flavivirus infections pose a significant global health burden underscoring the need for the development of safe and effective vaccination strategies. Available flavivirus vaccines are from time to time concomitantly delivered to individuals. Co-administration of different vaccines saves time and visits to health care units and vaccine clinics. It serves to provide protection against multiple pathogens in a shorter time-span; e.g., for individuals travelling to different endemic areas. However, safety and immunogenicity-related responses have not been appropriately evaluated upon concomitant delivery of these vaccines. Therefore, we performed an open label, non-randomized clinical trial studying the safety and immunogenicity following concomitant delivery of the yellow fever virus (YFV) vaccine with tick-borne encephalitis virus (TBEV) and Japanese encephalitis virus (JE) virus vaccines. Methods and findings Following screening, healthy study participants were enrolled into different cohorts receiving either TBEV and YFV vaccines, JEV and YFV vaccines, or in control groups receiving only the TBEV, JEV, or YFV vaccine. Concomitant delivery was given in the same or different upper arms for comparison in the co-vaccination cohorts. Adverse effects were recorded throughout the study period and blood samples were taken before and at multiple time-points following vaccination to evaluate immunological responses to the vaccines. Adverse events were predominantly mild in the study groups. Four serious adverse events (SAE) were reported, none of them deemed related to vaccination. The development of neutralizing antibodies (nAbs) against TBEV, JEV, or YFV was not affected by the concomitant vaccination strategy. Concomitant vaccination in the same or different upper arms did not significantly affect safety or immunogenicity-related outcomes. Exploratory studies on immunological effects were additionally performed and included studies of lymphocyte activation, correlates associated with germinal center activation, and plasmablast expansion.

Conclusions

Inactivated TBEV or JEV vaccines can be co-administered with the live attenuated YFV vaccine without an increased risk of adverse events and without reduced development of nAbs to the respective viruses. The vaccines can be delivered in the same upper arm without negative outcome. In a broader perspective, the results add valuable information for simultaneous administration of live and inactivated flavivirus vaccines in general.

Trial registration

Eudra CT 2017-002137-32 .

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Yellow Fever VaccineJapanese Encephalitis VaccinesEncephalitis, Tick-BorneFlavivirus InfectionsEncephalitis Viruses, Tick-BorneEncephalitis, JapaneseHumansAntibodies, ViralAntibodies, NeutralizingYellow fever virusVaccines, AttenuatedVaccines, Inactivated

Substanzen

Yellow Fever VaccineJapanese Encephalitis VaccinesAntibodies, ViralAntibodies, NeutralizingVaccines, AttenuatedVaccines, Inactivated

Autor:innen und Institutionen

  • Center for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden.
  • Karolinska Trial Alliance, Karolinska University Hospital, Stockholm, Sweden.
  • Department of Infectious Diseases, Karolinska University Hospital, Stockholm, Sweden.
  • Division of Immunology and Allergy, Department of Medicine Solna, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden.

ORCID-Profile: Hans-Gustaf Ljunggren

Förderung

  • Vetenskapsrådet
  • Stiftelsen för Strategisk Forskning
  • Region Stockholm
  • Karolinska Institutet

Zitieren

APA

Sandberg, J. T., Löfling, M., Varnaitė, R., Emgård, J., Al-Tawil, N., Lindquist, L., Gredmark-Russ, S., Klingström, J., Loré, K., Blom, K., & Ljunggren, H. G. (2023). Safety and immunogenicity following co-administration of Yellow fever vaccine with Tick-borne encephalitis or Japanese encephalitis vaccines: Results from an open label, non-randomized clinical trial. PLOS Neglected Tropical Diseases. https://doi.org/10.1371/journal.pntd.0010616

Vancouver

Sandberg JT, Löfling M, Varnaitė R, Emgård J, Al-Tawil N, Lindquist L, et al. Safety and immunogenicity following co-administration of Yellow fever vaccine with Tick-borne encephalitis or Japanese encephalitis vaccines: Results from an open label, non-randomized clinical trial. PLOS Neglected Tropical Diseases. 2023. doi:10.1371/journal.pntd.0010616

BibTeX
@article{Sandberg2023,
  author = {Sandberg, John Tyler and Löfling, Marie and Varnaitė, Renata and Emgård, Johanna and Al-Tawil, Nabil and Lindquist, Lars and Gredmark-Russ, Sara and Klingström, Jonas and Loré, Karin and Blom, Kim and Ljunggren, Hans-Gustaf},
  title = {Safety and immunogenicity following co-administration of Yellow fever vaccine with Tick-borne encephalitis or Japanese encephalitis vaccines: Results from an open label, non-randomized clinical trial},
  journal = {PLOS Neglected Tropical Diseases},
  year = {2023},
  doi = {10.1371/journal.pntd.0010616}
}
Kostenlos starten →